The EQ-5D is a standardized instrument for use as a measure of health outcome. Applicable to a wide range of health conditions and treatments, it provides a simple descriptive profile and a single index value for health status. It is a brief, simple and easy-to-use self-completion questionnaire consisting of five three-level items, representing various aspects of health: mobility, self-care, usual activities, pain/discomfort and anxiety/depression (mood).

The Eating Disorder Examination (EDE) is a semi-structured interview used worldwide for diagnostic purposes and to assess the core psychopathology of an eating disorder. The Eating Disorder Examination Questionnaire 6.0 (EDE-Q) has been developed as a self-report questionnaire version of the full-length interview.

A DSM-IV Criteria Checklist (modified from Hudziak et al., 1993) will be administered to determine the patient’s Axis I substance abuse and dependence diagnoses prior to enrollment.

This instrument begins with an assessment of whether the participant evidenced symptoms of Conduct Disorder prior to the age of 15 (which is required to meet DSM-IV criteria for Antisocial Personality Disorder). If the participant does evidence a history of Conduct Disorder, then the interview continues with an assessment of the DSM-IV criteria for Antisocial Personality Disorder.

The Drug Stroop Test is a Stroop color-naming task modified to include drug-related words. (Vadhan et al, 2007)

Compliance with standard CTP drug rehabilitation programs will be assessed by recording attendance at drug abuse counseling sessions on a weekly basis in the Drug Rehabilitation Compliance CRF (each week will have a separate CRF).

Participant liking of OROS-MPH/placebo will be assessed with the Drug Rating Questionnaire. This questionnaire is a derivative of the ARCI Benzedrine scales [Martin et al., 1971] to evaluate likeability and potential abuse based on the subjective response of the participant with ADHD. The Drug Rating Questionnaire is a visual analog scale that includes additional questions that assist in disentangling the therapeutic effects of the medication from the euphoria scales - an important confound as recently articulated by Kollins [2003] in children with ADHD. There are no currently psychometrically validated scales available for such purposes in ADHD adults. The Drug Rating Questionnaire has been used successfully in clinical trials of adults with ADHD.

"The Drug Abuse Screening Test (DAST) was designed to provide a brief instrument for clinical and non-clinical screening to detect drug abuse or dependence disorders. It is most useful in settings in which seeking treatment for drug use problems is not the patient's stated goal. The DAST provides a quantitative index of the severity of problems related to drug abuse other than alcohol. DAST scores are highly diagnostic with respect to a DSM diagnosis of psychoactive drug dependence. The DAST is available in both 20-item and 10-item formats; an Adolescent version is also available. In addition, the DAST provides a general measure of lifetime problem severity that can be used to guide further inquiry into drug-related problems and to help determine treatment intensity. It takes about 5 minutes to administer the DAST-20 and 2 minutes to score the DAST-10. NOTE re: history and alternate names: The original measure had 28 items and was adapted from the MAST. The 20-item version of the DAST was found to have psychometric properties comparable with the 28-item version, and is now commonly referred to as the DAST, or DAST-20. The DAST is also known as the Drug Use Questionnaire (DUQ) (DUQ-20 and DUQ-10). The DAST-10 was selected in 2012 by a group of researchers from the National Drug Abuse Treatment Clinical Trials Network (CTN) to serve as the recommended assessment tool for use in general medical settings. For more information, see http://ctndisseminationlibrary.org/display/819.htm."